Head-to-head comparisons of medication uses, side effects, warnings, and more.
Key takeaways
Dupixent (dupilumab) and Xolair (omalizumab) are both injectable medications used to treat various inflammatory and allergic conditions, but they work differently and have different uses. Dupixent (dupilumab) is a monoclonal antibody that blocks proteins responsible for inflammation, making it effective for conditions like eczema, asthma, and sinus congestion with nasal polyps. It is typically injected every other week or monthly. Xolair (omalizumab), on the other hand, targets immunoglobulin E (IgE) to prevent allergic reactions and is used for allergic asthma, chronic hives, and nasal polyps. It is usually injected every 2 or 4 weeks. While Dupixent (dupilumab) is available only as a brand-name medication, Xolair (omalizumab) also does not have a generic form. Common side effects of Dupixent include injection site reactions and eye inflammation, whereas Xolair can cause headaches, stomach pain, and dizziness. Additionally, Xolair has a risk of severe allergic reactions, which is less common with Dupixent.
Dupixent (dupilumab)
Xolair (omalizumab)
Dupixent (dupilumab)
Xolair (omalizumab)
Summary of Dupixent vs. Xolair
Summary for Interleukin antagonist
Prescription only
Dupixent (dupilumab) is an injection that helps treat certain inflammatory conditions. This includes eczema, asthma, and chronic obstructive pulmonary disease (COPD), among others. It's a biologic medication known as an interleukin antagonist that lowers inflammation. Dupixent (dupilumab) comes as prefilled pens and prefilled syringes. It's injected under the skin of the belly or thighs (or in the back of the upper arm with someone's help). The dosing schedule depends on the condition you have, your age, and your weight. It's injected either every week, every 2 weeks, or every 4 weeks. Side effects include injection site reactions and eye problems.
Summary for Immunoglobulin E (IgE) monoclonal antibody